Trial: 201805179

PNOC013 – A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma



Principal Investigator

Abdelbaki, Mohamed

Disease Site

Bones and Joints; Brain and Nervous System; Eye and Orbit; Ill-Defined Sites; Kidney; Liver; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Skin; Soft Tissue; Stomach; Unknown Sites

Learn more about this study at: